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Abstract
Background: Friedreich ataxia is an autosomal recessive hereditary spinocerebellar disorder, characterized by progressive
limb and gait ataxia due to proprioceptive loss, often complicated by cardiomyopathy, diabetes and skeletal deformities.
Friedreich ataxia is the most common hereditary ataxia, with a reported prevalence of 1:20 000 – 1:50 000 in Central
Europe. Previous reports from south Norway have found a prevalence varying from 1:100 000 – 1:1 350 000; no studies
are previously done in the rest of the country.
Methods: In this cross-sectional study, Friedreich ataxia patients were identified through colleagues in neurological,
pediatric and genetic departments, hospital archives searches, patients’ associations, and National Centre for Rare
Disorders. All included patients, carriers and controls were investigated clinically and molecularly with genotype
characterization including size determination of GAA repeat expansions and frataxin measurements. 1376 healthy
blood donors were tested for GAA repeat expansion for carrier frequency analysis.
Results: Twenty-nine Friedreich ataxia patients were identified in Norway, of which 23 were ethnic Norwegian,
corresponding to a prevalence of 1:176 000 and 1:191 000, respectively. The highest prevalence was seen in the
north. Carrier frequency of 1:196 (95 % CI = [1:752–1:112]) was found. Homozygous GAA repeat expansions in the
FXN gene were found in 27/29, while two patients were compound heterozygous with c.467 T < C, L157P and
the deletion (g.120032_122808del) including exon 5a. Two additional patients were heterozygous for GAA repeat
expansions only. Significant differences in the level of frataxin were found between the included patients (N = 27),
carriers (N = 37) and controls (N = 27).
Conclusions: In this first thorough study of a complete national cohort of Friedreich ataxia patients, and first
nation-wide study of Friedreich ataxia in Norway, the prevalence of Friedreich ataxia in Norway is lower than
in Central Europe, but higher than in the last Norwegian report, and as expected from migration studies. A
south–north prevalence gradient is present. Based on Hardy Weinberg’s equilibrium, the carrier frequency of
1:196 is consistent with the observed prevalence. All genotypes, and typical and atypical phenotypes were
present in the Norwegian population. The patients were phenotypically similar to European cohorts. Frataxin
was useful in the diagnostic work-up of heterozygous symptomatic cases.
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Background
Friedreich ataxia (FRDA) is an autosomal recessive spi-
nocerebellar disorder, and is reported to be the most
frequent of the large and heterogeneous group of her-
editary ataxias in Europe, the Middle East, the Indian
subcontinent in South Asia, and North Africa [1]. De-
generation of the dorsal root ganglia and spinal roots,
dorsal columns, spinocerebellar tracts, corticospinal
tracts and cerebellar dentate nucleus give rise to the
clinical picture of progressive limb and gait ataxia, pro-
prioceptive loss, absent tendon reflexes and dysarthria
[2–5]. The disease is often further complicated by
extra-neurological manifestations such as cardiomyop-
athy, diabetes and skeletal deformities [6]. FRDA is re-
ported worldwide with the exception of sub-Saharan
Africa and southeast Asia [7], and the prevalence in
Central Europe is estimated to be between 1:20 000 to
1:50 000. Its presence in Norway remains, however,
poorly documented. Whereas Skre reported a preva-
lence of 1:100 000 in the western part Norway in 1975
[8], Koht did not find any ethnic Norwegian cases in
southeast Norway in 2007 [9], and Erichsen et al. found
a prevalence of 0.15:100 000 in the same region in 2008
[10]. However, molecular testing was not available until
1996 [11], thus Skre’s report may have included pheno-
copies, for instance patients with ataxia due to POLG
mutations [12]. Nonetheless, a FRDA prevalence of
1:208 000 is expected in Norway based on migration
studies, which is higher than in other Nordic countries
[13] (Table 1). Health authorities depend on reliable
epidemiological data for planning and making strategies
for present and future health care, especially for imple-
mentation and funding of future treatments. Though
there is still no specific curative treatment available for
FRDA today, several drugs are under current investiga-
tion. It is of paramount importance as for all rare dis-
eases to identify patients – both to ensure the best
present clinical practice follow-up, and to be able to
offer them state of the art new treatments when these
emerge. A thorough characterization of the cohort is
also required for participation in future clinical trials.
The classic FRDA phenotype, as described by Harding’s
clinical criteria, included onset before the age of 25,
progressive ataxia, absent knee and ankle jerks, axonal
neuropathy and dysarthria [6]. The phenotypical spectrum
of FRDA widened after the discovery of the disease-
causing mutations in the FXN gene. Today, 15 % of
cases are described with onset later than 25 (Late-onset
FRDA (LOFA)) or 40 years of age (very late-onset
FRDA (VLOFA)), and other atypical presentations as
FRDA with retained reflexes (FARR) are also reported
[14]. 96-98 % of FRDA cases are caused by homozygous
GAA triplet repeat expansions in the first intron of the
FXN-gene, while the remaining present compound het-
erozygosity with GAA-expansions and point mutations
or deletions [11, 15–17]. The mutations lead to de-
creased transcription of frataxin mRNA, subsequently
leading to lower levels of the mitochondrial protein fra-
taxin. The biological role of frataxin is not yet com-
pletely understood [18], but it is known to have a role
in iron-sulphur (Fe-S) cluster biogenesis in the mito-
chondria. Lack of frataxin causes iron accumulation
and impaired electron transport in the respiratory chain
in the mitochondria, further leading to increased for-
mation of toxic free radicals and oxidative stress [19].
The frataxin level in multiple cell types, including blood
cells and fibroblasts, appears to be correlated with the
frataxin level in disease-affected tissues [20]. This level
is low in FRDA patients, while healthy carriers show
intermediate frataxin levels [21]. It is suggested that fra-
taxin level may be useful in diagnostics or follow up of
patients [22], as it represents a standardized biochem-
ical marker.
Disease causing alleles of FXN usually have between
70–1500 GAA repeats [4, 23]. Fifty % of the variation in
phenotype severity is estimated to be due to the GAA
expansion size [24], with the size of the smaller allele
showing the strongest correlation [3, 25]. Frataxin levels
are also found to be inversely correlated with GAA re-
peat length [21]. Normal alleles can be divided into
Short Normal (SN) alleles containing up to 12 GAA re-
peats in the majority of healthy individuals, and Long
Normal (LN) alleles with up to 33 GAA repeats. Alleles
between 34 and 65 GAA repeats can act as unstable pre-
mutation alleles. Both LN alleles, premutation alleles
and expanded alleles have shown linkage disequilibrium
for the same nearby alleles, suggesting a common origin
[7, 26]. LN alleles reaching the instability threshold esti-
mation of 34 may therefore function as a mutation reser-
voir in the population giving rise to new pathogenic
expansions in intergenerational transmission [27].
In order to ensure the best clinical practice and
follow-up, the epidemiological, clinical, and molecular
characteristics of FRDA patients in Norway was investi-
gated. The first objective of this study was to establish
the prevalence and carrier frequency of FRDA in Norway
through a population-based epidemiological study. The
Table 1 Published and estimated FRDA prevalence numbers
from Nordic countries
Country Prevalence Predicted FRDA prevalencea [13]
Norway [8, 10] 1:100 000–1:1 350 000 1:208 860
Denmark [63] 1:140 000 1:132 540:
Sweden [42] 1:420 000 1:410 027
Finland [43] 1:750 000 -
Iceland [64] 1:93 600 -
a (based on R1b haplotype)
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second objective was to establish a Norwegian control
material for frataxin measurements in whole blood, and
assess the level in whole blood in all of affected sub-
jects, carriers and healthy controls. The last objective of
this study was to assess GAA repeat expansion sizes,
both in the patients and in the background population.
In addition, we wanted to relate the patients’ genotypes
to their clinical and molecular phenotypes, and to com-
pare the Norwegian patients with other case series.
Methods
Patients and controls
As shown in Fig. 1, three main sources were used to
identify FRDA patients:
a. Clinical search: At the time of the study there were
altogether 22 different public hospitals in Norway
which had either a general pediatric (20 departments)
or a general neurological (19 departments)
department, or both. Six of these were university
hospitals. All departments were contacted by
postal mail first in September 2011, with follow-up by
telephone during 2011. Patients’ organizations and the
National center for rare diagnoses, so called Frambu,
were contacted during the second half of 2011, and
the project was presented at the national neurological
meeting in 2013 to ensure good recruitment of
patients. The investigators were continuously
informed about newly diagnosed patients from
these sources until prevalence date, November
30th, 2014.
b. Computer search: Searches were performed based
on electronic coding systems in hospital archives,
with searches for “334.0 Friedreich ataxia” in ICD-9,
Fig. 1 Flowchart showing patient ascertainment and the Friedreich ataxia population in Norway
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and G11.1 “Cerebellar ataxia with early age of onset
(incl. FRDA)” in ICD-10. Searches were performed
during the second half of 2011.
c. Laboratory search: The three laboratories offering
FXN – gene analysis in Norway at prevalence date,
November 30th, 2014, were contacted twice; first in
October 2011, then at prevalence date to identify
newly diagnosed patients within the study period.
All individuals with positive findings from the
establishment of the method to this date were
further investigated.
Eligible for inclusion were all affected subjects with
ataxia symptoms, at least one pathological expansion > 66
GAA-repeats in the FXN gene, and alive on November 30,
2014 (n = 31). Patients with no GAA repeat expansions in
the FXN gene were excluded. Healthy carriers consisted of
1st degree relatives of the patients aged > 18 years
who were heterozygous for mutations in the FXN
gene (n = 37). The controls (n = 27) were healthy age-
matched individuals, recruited among friends and col-
leagues. All subjects were interviewed and examined
by the neurologist IMW.
1376 healthy anonymous ethnic Norwegian blood do-
nors from Oslo were used in the carrier frequency study.
The data of the Norwegian background population are
from Statistics Norway [28] on January 1st, 2014.
Ethics, consent and permissions
Written informed consent was obtained from all study
participants or their authorized guardians. The study
was approved by The Regional Committee for Research
Ethics (Ethical agreement n°129/04011), in Norway.
Clinical examination
All identified patients who met the inclusion criteria
were invited to participate in the study. Clinical data
were systematically registered according to the SPATAX
network’s diagnostic form for spinocerebellar degener-
ation [29, 30] including the Scale for the Assessment
and Rating of Ataxia (SARA) [31]. Associated symptoms
like signs of cardiomyopathy at echocardiogram, scoli-
osis, diabetes, dysphagia, hearing loss and psychiatric
problems were carefully registered by interview and the
patients’ medical charts, as shown in Table 2.
Molecular analyses
All patients were tested for GAA triplet repeat expan-
sions to confirm their genetic diagnosis. The methods
used were standard polymerase chain reaction (PCR), for
detection of alleles in normal range, and Southern blot or
TP PCR (Triplet Repeat Primed PCR) for detection of ex-
panded alleles. All patients that were heterozygous for the
GAA triplet repeat expansion, were subsequently analyzed
by Sanger sequencing of the coding region including
exon-intron boundaries, for detecting of sequence vari-
ants, and by Multiplex ligand-dependent probe amplifica-
tion (MLPA) for detection of deletions/duplications. The
reference sequence NM_000144.4 was used.
Analyses for expanded GAA repeats were performed
by standard PCR method, using AmpliTaq Gold 360
(Applied Biosystems, Foster City, USA). Primer se-
quences and PCR conditions used for sequencing are
available on request. TP PCR was performed as de-
scribed by Ciotti P.et al. [32]. Sanger sequencing was per-
formed using BigDye Terminator v.3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, USA). SALSA MLPA
P316 (MRC Holland, The Netherlands) was used ac-
cording to the manufacturer’s instructions to detect
single or multiple deletions/duplications of the FXN
gene. Size determination of expanded alleles in patients
and carriers was analyzed by Southern blot [33].
GAA expansion size
Determination of GAA repeat lengths of the shortest allele
(GAA1) and longest allele (GAA2) was done in all patients,
carriers and controls for phenotypic characterization. The
number of GAA repeats in the normal range was deter-
mined by PCR amplification followed by analysis by ca-
pillary electrophoresis. Expanded alleles were analyzed
by Southern blot. The GAA repeat sizes as measured
by PCR were calculated relative to a standard size ladder
(GS500-ROX35-250, Applied Biosystems). In Southern
blot analyses, smear length was converted to GAA repeat
size by dividing kb with three.
Transmission instability
The degree of meiotic instability of GAA repeats was
assessed by analyzing differences in GAA repeat expan-
sion sizes in parents and children. As information of
the parental origin of alleles was not present, the min-
imal alteration possible was presumed in every trans-
mission, as previously done [34]. Only expansions or
retractions above a threshold of 0.3 kb (100 GAA
repeats) were registered, because most of the larger
expansions appeared as smears on the blot, and it was
difficult to estimate the exact number of repeats. The
results are shown in Additional file 1.
Carrier frequency study
DNA from 1376 healthy anonymous blood donors
was analyzed by TP PCR, and subsequently standard
PCR for those with expanded alleles to exclude
homozygosity. The normal alleles were sorted into
Short Normal (SN – fewer than 12 GAA-repeats) and
Long Normal (LN – 12 to 34 GAA-repeats), and pre-
mutation alleles (35–66 GAA-repeats) to find the pro-
portion of possible unstable LN alleles.
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Table 2 Clinical characteristics of included Friedreich ataxia patients in Norway at time of study
Family –
patient
Gender Age at
onset
(in years)
Duration
(in years)
SARAa Presenting
symptom
Disability
stageb
Extensor
plantar
response
Reduced
virbratory
sense
Dysphagia Dysarthria Scoliosis Diabetes Depression Heart
involvement
Frataxin
pg/mcg
GAA
repeats,
Allele 1
GAA
repeats,
Allele 2
1-1 F 6 11 19 Cardio
myopathy
4 Bilateral y n y y n y y 0.126 700 700
2-1 M 8 8 19 Unsteady 4 Bilateral y y y y n n n 0.150 570 870
3-1 F 7 10 23 Unsteady 5 Bilateral y y y y n n n 0.135 740 1000
4-1 M 18 11 25.5 Unsteady 5 Unilateral y y y y n y y 0.305 640 640
4-2 M 2 15 31 Unsteady 6 Equivocal y y y y n n y 0.045 700 700
5-1 M 4 17 28 Unsteady 6 Bilateral y n y y y n n 0.079 700 700
6-1 F 6 8 14.5 Unsteady 4 Unilateral y n y y n y n 0.132 700 700
7-1 M 3 20 33 Unsteady 6 Bilateral y y y y n y y 0.042 800 800
8-1 F 6 6 11.5 Unsteady 3 Normal n n n y n n n 0.084 800 800
9-1 M 17 9 11 Unsteady 4 Equivocal y n n n n n n 0.207 370 700
10-1 M 6 12 12.5 Unsteady. 3 Bilateral y y y y n y y 0.130 770 770
11-1 M 15 4 9 Unsteady 2 Normal n y y y n n n 0.307 340 940
12-1 M 10 59 31 Unsteady 6 Unilateral y y y y n y y 0.256 340 800
13-1 F 12 19 32 Unsteady 6 Bilateral y y y y n n n 0.020 700 1040
13-2 F 10 23 38.5 Unsteady 6 Bilateral y y y y n y n 0.068 740 740
14-1 F 20 11 10.5 Unsteady 3 Bilateral y y y y n n n 0.904 400 400
14-2 F 20 9 13.5 Unsteady 3 Bilateral y y y y n y n 0.826 340 340
15-1 M 15 7 28 Unsteady 6 Bilateral y y y n n n y 0.103 670 870
16-1 M 5 9 12.5 Unsteady 3 Normal y y y y n n y 0.179 470 870
17-1 F 5 6 11 Unsteady 2 Normal y n n n n n n 0.058 700 700
18-1 M 15 33 33 Unsteady 6 Bilateral y y y y n n n 0.180 540 940
19-1 F 17 17 24 Unsteady 5 Unilateral y y y n n n n 0.323 340 800
20-1 F 5 6 6.5 Unsteady 2 Bilateral y n y y n n y 0.109 700 700
21-1 M 13 18 31 Unsteady 5 Bilateral y y y y n n y 0.215 700 700
22-1 M 4 21 32 Unsteady 6 Bilateral y y y y y y y 0.031 740 c.467T>C
23-1 F 7 33 30 Unsteady 6 Bilateral y y y y n n y 0.126 770 g.120032_
122808del
24-1 F 3 9 14 Cardio
myopathy
3 Normal y y y y n n y na na na
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Table 2 Clinical characteristics of included Friedreich ataxia patients in Norway at time of study (Continued)
Summary
mean (SD)
or %
M: 52 %
F: 48 %
9.6
(5.7)
15.2
(11.6)
21.6
(9.6)
Unsteady: 93 %
Cardiomyopathy: 7%
4.4
(1.5)
Bilateral: 59 %
unilateral: 15 %
Equivocal: 7 %
normal: 19 %
93 % 93 % 89 % 85 % 7 % 33 % 48 % 0.198
(0.214)
615
(161.8)
759
(160.6)
aSARA (Scale for the Assessment and Rating of Ataxia)
bDisability stage 1-7: 1:(no disability), 1:(no functional handicap but signs at examination, 2:(mild, able to run, walking unlimited), 3:(moderate, unable to run, limited walking without aid), 4:(severe, walking with one
stick), 5:(walking with two sticks), 6:(unable to walk, requiring wheelchair), 7:(confined to bed)
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Frataxin protein level
Frataxin level in whole blood was measured by Frataxin
protein quantity dipstick assay kits (MitoSciences
(MSF31), Abcam, Cambridge, UK). Whole blood was
collected from patients, carriers and controls in K2
EDTA BD Vacutainer tubes (REF 454209). The patients’
and carriers’ samples were stored in room temperature
for 2 to 7 days while they were sent to our center by postal
mail, immediately frozen at −20 °C at reception, and
thereafter stored at −80 °C. The time of storage of the
control samples were matched to the patient/carrier sam-
ples. Recombinant human frataxin full-length protein
(ab110353, Abcam) was diluted 1:2 for generation of
standard curve. Briefly, 50 μl of whole blood was mixed
with 150 μl of ice cold extraction buffer. After clarifying
the extracts by centrifugation at 14500 RPM for 20 min
at 4 °C, the supernatant was collected and 0.5 μl of
Sigma P8340 protease inhibitor (Sigma, St. Louis, MO)
was added. The samples were analyzed as described in
the protocol provided by the manufacturer [21, 35].
The immunecaptured frataxin was quantified with a
Hamamatsu immunochromato reader (MS1000 Dipstick
reader, Abcam). Samples were analyzed in triplicates, and
the median value was selected for the final calculation. A
logarithmic standard curve ranging from 0.4 – 100 ng/ml
frataxin was used. The total protein quantity in each lysate
was determined using the BCA Protein Assay Kit (23225,
Pierce Biotechnology, Rockford, IL).
Statistical analysis
Statistical analysis of clinical data and the frataxin assay
was performed using Statistical Package for the Social
Sciences (SPSS) v.22 (IBM, Armonk, NY, USA) or Graph
Pad Prism (Graph Pad Software, Inc., San Diego, CA). A
p-value of < 0.05 was set as the threshold for signifi-
cance. Chi square or Fisher’s exact test were used when
comparing the epidemiological proportions (north vs.
south, ethnic vs. non-ethnic Norwegians and male vs.
female transmission). Fisher’s exact test was used when
expected frequencies were less than five in one or more
cells. Mann Whitney U test was used when comparing
continuous variables like clinical characteristics between
groups of patients (ethnic vs non-ethnic Norwegians, male
vs female), as well as in comparisons of frataxin level be-
tween patients, carriers and controls after Kruskal-Wallis
test was performed. Correlations between disease dur-
ation, age at onset, neurological severity (SARA score),
molecular characteristics (GAA repeat length, frataxin
level) and the presence of non-neurological complications
like scoliosis, heart involvement and diabetes were
assessed with Spearman’s rho. In correspondence with Co-
hen, the size of correlation coefficient r is interpreted as
0.10-0.29 = small, 0.30-0.49 =medium, and >0.50 = large.
To examine the relationship between frataxin level and
the significant predictors we used multiple regression
analysis. Receiver operating characteristic (ROC)-curves
were used to select cutoff values for the frataxin mea-
surements, calculating area under the ROC curve, sen-
sitivity and specificity.
Power analysis calculating the size of the blood donor
sample for carrier frequency analysis was done with the
help of a statistician.
Results
Epidemiological data
Prevalence
As shown in Fig. 1, 31 patients from 28 unrelated fam-
ilies with ataxia symptoms and at least one allele with
pathological GAA repeat expansion in the FXN-gene
were identified as alive on prevalence date. In 30/39 of
the contacted hospital departments, either the head of de-
partment or the doctor in charge of ataxias consulted with
their colleagues whether they were aware of FRDA pa-
tients, and answered our query. In eight of the remaining
departments, electronic searches based on ICD diagnosis
coding in hospital archives including both inpatients and
outpatients, were performed. Only one smaller depart-
ment in the south of Norway did not respond. However,
this department only has an out patients clinic for neur-
ology. Moreover neurologists have been referring their
ataxia patients to our university hospital. In all six univer-
sity hospitals in Norway, representatives from all neuro-
logical and pediatric departments answered the query.
Additionally, electronic searches were performed in four
departments in university hospitals. Due to legal reasons
these searches were done by local clinicians. The elec-
tronic searches in Oslo University Hospital (OUS) were
made by IMW. 17 of all 31 patients from all over the
country were identified in the OUS’ archives, truly mostly
due to the tertiary specialist function of OUS for these
rare ataxia patients. Through ICD-9, 14 patients were
identified at OUS, only two of them eligible for inclusion
and alive. The G11.1-code in ICD-10 showed 121 hits at
OUS; 17 of the 18 patients eligible for inclusion were alive,
including the two identified by ICD-9 codes.
The clinical departments, the National center for rare
diagnoses and patients’ organizations informed continu-
ously about all new diagnosed patients between 2011
and November 30th 2014.
Among the different sources, 30/31(97 %) patients
were identified through colleagues in clinical departments,
21/31 (68 %) were identified through the National center
for rare diagnoses, Frambu, and 27/31 (87 %) were regis-
tered in genetic departments. Thus clinical departments
were the most powerful source, but only two patients
were identified exclusively through this source. All other
patients were identified through at least two different
sources. Twenty-seven were confirmed homozygous for
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GAA repeat expansions. Four patients were heterozy-
gous for GAA repeat expansion. Two of these patients
were identified as being compound heterozygous; one
had a mutation c.467 T < C, p.L157P (Table 2: Patient
22–1) and the other had a deletion (Patient 23–1), both
in trans. The deletion was confirmed by long-range
PCR to be consistent with the deletion of 2776 bp
(g.120032_122808del) including exon 5a. The remaining
two heterozygous patients had normal findings by Sanger
sequencing and MLPA of the FXN-gene, and were not in-
cluded in the prevalence number. One of these also car-
ried a previously reported pathogenic OPA1 mutation
[36]. Thus, FRDA was genetically confirmed in 29 of 31
individuals (15 males, 14 females), while two individuals
were heterozygous for GAA repeat expansion.
Of the confirmed FRDA patients 23 were ethnic
Norwegians, three were Caucasians from other European
countries while three were non-Caucasians from the
Middle East and North-Africa. As shown in Fig. 2,
total prevalence in Norway was 1:176 000 (population:
5 109 056 on 1.1.2014), with a significant difference
between north and south (southeast + west) Norway (p =
0.0008). Prevalence was similar in the ethnic Norwegian
population (1:191 000 (population: 4 398 591 on 1.1.2014)),
and non-ethnic Norwegian population (1:118 410 (popula-
tion: 710 465 on 1.1.2014)) (p = 0.29).
Carrier frequency study
Seven expanded FXN alleles were found among 2752 al-
leles from healthy ethnic Norwegian blood donors in Oslo,
corresponding to an observed carrier frequency of 1:196
(95 % CI = [1:752–1:112]). The observed FRDA prevalence
among ethnic Norwegians in southeast Norway was 1:314
714 (population on 1.1.2014: 2 203 000). Hardy Weinberg
equilibrium (HWE) estimation of the carrier frequency in
the southeast Norwegian population is 1:281, which is
within the confidence interval of the observed carrier fre-
quency. In the entire ethnic Norwegian population the
HWE estimated carrier frequency is 1:210.
There were 454 long normal alleles (LN) with an expan-
sion size of 12–34 repeats, of which 38 were longer than
27 repeats (Table 3). Three (0.11 %) alleles were between
34 and 66 repeats, classified as premutation alleles.
Characterization of phenotype
Twenty-seven of 29 genetically confirmed FRDA pa-
tients (25 homozygous and 2 compound heterozygous)
agreed to participate in the clinical part of the study.
These had a median age on prevalence day of 22 years,
and a median age at onset of 7 years, with no late onset
cases (>25 years of age). Seven patients had a positive
family history of FRDA (siblings) and 3 patients reported
consanguinity (Table 4).
Fig. 2 Total and regional FRDA prevalence in Norway on 30.11.2014
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Twenty-five of 27 patients had typical FRDA according
to Harding’s diagnostic criteria [6], while two were atyp-
ical due to brisk reflexes consistent with FARR (Table 2:
Patient 14–1 and 14–2). The mean SARA score was
21.6. Regarding non-neurological complications, two pa-
tients had confirmed diabetes; one of them was com-
pound heterozygous with a point mutation. 23/27 had
scoliosis; five of them had been treated with spine surgery.
Cardiomyopathy was confirmed in 14/26 patients by
echocardiography, mostly as asymptomatic hypertrophy.
However, four had atrial fibrillation, further complicated
by stroke in one patient in his fifties (Patient 12–1), and
cardiac infarction in one patient at age 25 (Patient 22–1).
Nine patients had depression necessitating treatment. All
clinical parameters as reported in Table 4 were similar in
ethnic and non-ethnic Norwegians. There were no signifi-
cant gender differences in disease duration, SARA score,
age at onset, cardiomyopathy, scoliosis, depression, fra-
taxin level nor GAA repeat lengths. There were no obvi-
ous differences in the Norwegian patient series compared
to the previously described case series reported in Table 4
[3, 6, 14, 34, 37–41].
Molecular and biochemical characterization
Molecular analyses were done in 29 patients (including
two heterozygous for GAA repeat expansion), 37 healthy
1st degree carrier relatives (19 mothers, 13 fathers, 3 sib-
lings, and 2 children of the patients) and 27 healthy con-
trols (mean age 25.9 years, male–female ratio: 1:2.7).
GAA repeat expansion size
In 29 patients (27 GAA repeat expansion homozygous
and two compound heterozygous) the GAA1 repeat
length ranged from 340 to 740, GAA2 (n = 25) from 340
to 1040, while healthy carriers showed 240 to 1040 repeats
in the expanded allele (Additional file 1). Alleles from 27
healthy controls ranged from 7 to 22 GAA repeats.
Frataxin protein level
Figures 3a and 4 show that frataxin levels in whole blood
differed significantly between FRDA patients, FXN mu-
tation carriers and healthy controls. Two outliers in the
patient group were FARR patients with a mean frataxin
level of 0.86 pg/μg, while the classic homozygous GAA
repeat expansion patients (cFRDA) had a mean frataxin
level of 0.14 pg/μg. Healthy carriers showed a mean
frataxin level of 0.8 pg/μg, and healthy controls showed
a level of 1.69 pg/μg.
ROC curves were constructed to select cut-off values
for frataxin levels in order to assess the ability of the mea-
surements to separate between “disease” and “no disease”
(Additional file 2). Two curves were constructed, first to
distinguish between FRDA patients from controls and
carriers combined, and secondly to distinguish between
FRDA and carriers combined from healthy controls, as
previously shown [22]. Comparison of FRDA patients ver-
sus controls/carriers, resulted in a 92.3 % sensitivity and a
96.9 % specificity for a cut-off value of frataxin of 0.35 pg/
μg (p < 0.0001, area = 0.968), while comparison of FRDA
patients/carriers with controls, resulted in a 92.1 % sensi-
tivity and a 92.6 % specificity for a cut-off value of
1.19 pg/μg (p < 0.0001, area = 0.968).
Correlations
Disease duration was strongly positively correlated to
SARA (r = 0.817, p = <0.0001) and clinical stage (r = .784,
p = <0.0001).
At the molecular level, frataxin level was strongly posi-
tively correlated to age at onset (r = 0.745, p = <0.0001)
and age at wheelchair bound (r = 0.856, p < 0.0001).
Frataxin was also negatively correlated to neurological
severity with total SARA score (r = −0.390, p = 0.049), as
well as to the sub-scores SARA nose-finger test (r =−0.440,
p = 0.025), SARA stance (r = −0.404, p = 0.041), and SARA
sitting (r = −0.439, p = 0.025). Additionally, frataxin was in-
versely correlated to the presence of impaired touch and
prick sense (r = −0.544, p = 0.004).
A strong inverse correlation was found between
GAA1 length and age at onset (r = −0.634, p = 0.001).
No correlation was found between SARA score and
the length of any of the expanded alleles. Frataxin
level was also strongly negatively correlated to the
GAA1 length (r = −0.674, p = 0.0002) (Fig. 3b), but
not to GAA2 length (data not shown) in FRDA pa-
tients. In healthy carriers a moderate and significant
negative correlation between frataxin level and allele
size was present(r = −0.337, p = 0.048), but not in nor-
mal controls (r = −0.135, p = 0.503) (Fig. 3b).
The only factor that was related to extra-neurological
features was the moderate negative association be-
tween heart involvement and age at onset (Spearmans
rho −0.396, p = 0.041). Otherwise, no relationships
Table 3 Distribution of the frequencies of the GAA repeat sizes in normal alleles in 6 different populations
Normal alleles Norwegian (present study) Finnish [43] Cuban [65] Indian [66] Caucasian [67] French [26]
North South
GAA repeat sizes 5-12 83.5 % 83 % 79.5 % 89.1 % 94.1 % 80 % 83 %
13-34 16.5 % 17 % 20.5 % 10.9 % 5.9 % 20 % 17 %
Alleles range 6-34 6-27 7-27 5-31 7-16 5-23 7-34
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Table 4 Reports of phenotypes in Friedreich ataxia patients in Norwegian patients compared to other case series
Clinical feature Harding
[6]
Filla
et al. [37]
Dürr
et al. [3]
Schöls
et al. [34]
Lamont
et al. [14]
2Delatycki
et al. [38]
McCabe
et al. [39]
Salehi
et al. [40]
Reetz
et al. [41]
Present study
Country of study UK Italy France Germany UK Australia Ireland Iran Europe
(EFACTS)
Norway
Year of publication 1981 1990 1996 1997 1997 1999 2000 2014 2015 2015
No of patients 115 80 140 38 56 51 58 22 592 27
Genetically confirmed diagnosis No No Yes Yes Yes Yes Yes Yes Yes Yes
Age at onset (years),
Mean(range),Median[interquartile
range]a
10.52 (1.7-27) 11.6 (2-23) 15.5 (2-51) 14.15 (5-36) 3 to 30 10.5 (SD±6.4) (1-26) - 10.8 (2-23) 15.7 (SD±10.4),
13 [9-19]
9.6 (2-20)
Age at examination (years),
Mean(range),Median[interquartile
range]a
- 25 (8-55) - - - - - - 33.9 (SD±10.2)
32 [23-43]
24.8 (11-69)
Disease duration (years),
Mean(range),Median[interquartile
range]a
22.0 (SD±12.8)
(2-61)
13.4 15.5 19.7 (SD±8.8) (5-42) 13.6 (SD±9.9) - - - 18.3 (SD±10.4)
17 [10-25]
15.2
(4-59)
Male:female 1:1.2 1:0.7 1:1.1 1:1.4 - 1:0.8 - 1:0.6 1:1.2 1:0.9
SARA (Standardized Rating Scale
of Ataxia), mean(range),
Median[interquartile range]
- - - - - - - - 23 [13-21] 21.6
(6.5-38.5), 23
[13.8-32.3]
Disability stage (1-7)b, Median - - - - - - - - 5 5
GAA repeats shortest allele,
Mean(range), Median[interquartile
range]a
- - 630 (SD±230) 800 (66-1360) 2-5 kb 739 (SD±191) 762 (333-1053) 594 (247-981) 648 [384-800] 614.6 (340-800),
700 [556-844]
GAA repeats longest allele,
Mean(range), Median[interquartile
range]a
- - 890 (SD±230) - 2-5 kb 973 (SD±162) 885 (534-1200) - 912 [789-1050] 759.2 (340-1040),
755 [670-840]
Frataxin level in whole blood
(pg/μg)
- - - - - - - - - 0.198
Homozygous GAA-repeat ex-
pansion (%)
- - - - - - - 100 97 93
Family history of FRDA (%) - 23.4 - - - - - - 32 20
Consanguinity (%) - 28.1 - - - - - - - 7
Intake of Idebenone (%) - - - - - - - - 27 52
Gait ataxia (%) 100 100 100 100 100 100 100 100 - 100
Limb ataxia (%) 99 94 99 100 100 100 - 100 - 100
Dysarthria (%) 97 84 91 100 91 95 93 95 - 89
Lower limb areflexia (%) 99 100 87 84 87 98 86 100 - 93
Extensor plantar reflexes (%) 89 75 79 95 96 73.5 93 90 - 74
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Table 4 Reports of phenotypes in Friedreich ataxia patients in Norwegian patients compared to other case series (Continued)
Reduced vibratory sense (%) 73 91 78 83 87 88 89 63 - 93
Scoliosis (%) 79 94 60 84 - 78 84 - - 85
Foot deformity (%) 55 90 55 82 - 74 79 54 - 81
Gaze-evoked nystagmus (%) 20 29 40 39 - - 40 45 - 18.5
Fixation instability (%) - - - 69 - - - - - 51.8
Saccadic pursuit eye
movements (%)
12 - 30 32 - - 52 - - 67
Dysphagia (%) - 30 27 76 - - - - - 78
Diabetes (%) 10 14 32c 6 - 8 7 4.5 - 7
Cardiomyopathy
(echocardiography) (%)
66d 28 63 75 - 65 67 - - 48 (n=26)
Hearing loss (%)e 8 9 13 39 - - - - - 26
Reduced vision (%)e 18 13 6 - - - 9 - 22
Psychiatric symptoms (%)f - - - - - - - - - 37
Atypical (%) - - 24 25 - 8 - - - 7
Wheelchair bound (%) 72 43 - 78 - 55 - 45 - 52
Age when wheelchair-bound
(years)
25.1 (SD±15.5) 26.3 (SD±7.8) 26.3 24.0 (SD±5.7) - 19.0 (SD±6.4) - - - 20.9 (SD±7.7)
Disease duration to
wheelchair-bound
(years)
15.5 (SD±7.41) 13.8 (SD±5.8) 10.8 (SD±6) 11.3 (SD±4.1) - 10.1 (SD±4.4) - - - 11.1 (SD±6.4)
Prognosis indexg 0.31 0.31 - 0.25 - - - - - 0.29
aUnless otherwise stated (SD=Standard deviation)
bDisability stage 1-7: 1:(no disability), 1:(no functional handicap but signs at examination, 2:(mild, able to run, walking unlimited), 3:(moderate, unable to run, limited walking without aid), 4:(severe, walking with one
stick), 5:(walking with two sticks), 6:(unable to walk, requiring wheelchair), 7:(confined to bed)
cimpaired glucose tolerance?
din Hardings study based on abnormal ECG, except for 9.6 % where ECG changes regarded insignificant
eBased on information given by the patients
fRequiring psychiatric treatment
gPrognosis index: mean disease duration in all patients in the case series/proportion of wheelchair-bound patients in the case series
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were found between extra-neurological features (foot
deformities, scoliosis or heart affection) and age at
onset, disease duration, clinical severity, GAA sizes,
or frataxin level.
A multiple linear regression analysis was performed to
identify possible predictors of frataxin level. Due to the
strong association between GAA1 and age at onset, two
multivariable models were needed to avoid multicolli-
nearity problems. In model 1 which included age at on-
set and SARA as possible predictors, 61 % of the
variance within frataxin level was explained by these
two factors (R2 = 0.608), with age at onset (regression
Fig. 4 Frataxin amounts in percentage of average amounts in
healthy controls in subgroups of carriers and patients. The graph
displays the mean relative frataxin amounts for the indicated
subgroups of carriers and patients; Healthy controls (N = 27), Healthy
carriers (N = 37), pFRDA carrier = healthy carrier with heterozygous
point mutation in the FXN gene (N = 1), delFRDA carrier = healthy
carrier with heterozygous deletion in the FXN gene (N = 1),
cFRDA = classic FRDA (N = 22), FARR = Friedreichs ataxia with
Retained Reflexes (N = 2), pFRDA = compound heterozygous with
point mutation (N = 1), delFRDA = compound heterozygous with
deletion (N = 1), Carriers with symptoms (N = 2)
Fig. 3 Frataxin levels in whole blood in FRDA patients, carriers and
controls. The frataxin level is significantly different between the
three groups and correlates with number of GAA1 repeats in FRDA
patients and healthy carriers. The levels of frataxin were measured
in blood from FRDA patients (N = 26), healthy carriers (N = 37) and
healthy controls (N = 27). a The Tukey box plot shows pg frataxin
per μg (mcg) total protein. The whiskers extends to a maximum of
1.5 x interquartile range (IQR) beyond the edge of the box (“Tukey’s
inner fence”). Values outside these fences represent outliers and are
marked as dots. b Linear regression analyses were performed to
analyze the correlation between frataxin levels (pg/mcg) in blood and
number of GAA1 repeats in FRDA patients (upper plot), number of
GAA2 repeats in healthy carriers (middle plot) and number of GAA2
repeats in healthy controls. R2 = coefficient of determination
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coefficient: 0.026 (95 % CI = [0.016–0.037]), p = <0.001) as
the strongest predictor, while SARA showed lower
influence (regression coefficient: −0.07 (95 % CI = [−0.013–
-0.001]), p = 0.035). Model 2 included two variables, GAA1
size and SARA, and these factors explained 48 % of the
variance within frataxin level (R2 = 0.484). Within this
model, GAA1 size was the strongest predictor (regression
coefficient −0.001(95 % CI = [−0.001– -0.0004]), p = 0.01),
while the effect of SARA was not significant (regression
coefficient −0.004 (95 % CI = [−0.011–0.004]), p = 0.331) in
the model.
Transmission instability
The degree of meiotic instability of GAA repeats in the
transmission from parents to children was assessed in 21
families with transmission analysis from healthy carrier
parents to affected children in 11 mother/father/child-
trios and 9 mother/child duos. In addition, the transmis-
sion from an affected parent to healthy carrier children
was analyzed in 2 father/child duos (Additional file 1).
The maximum expansion size was 200 and the max-
imum retraction size was 300 GAA repeats. As haplo-
type phasing was not available, the minimum possible
change was registered, which probably represents an
underestimate [34]. No cases of expansion from premu-
tation alleles to expanded alleles were observed.
Discussion
In this first study of Friedreich ataxia in the entire
Norwegian population, the prevalence result interest-
ingly supports prevalence estimates based on migration
studies, although an unexpected south–north prevalence
gradient is seen. The carrier frequency estimate is in
concordance with the estimated prevalence, suggesting
a good diagnostic coverage. This study is not only the
first comprehensive study of genetically confirmed
FRDA in Scandinavia, but also one of the first clinical
and molecular descriptions of a complete national
collection of FRDA patients.
Epidemiology
The study confirms the presence of FRDA in ethnic
Norwegians, contrary to what was suggested previously
[9]. The thorough epidemiological approach described in
Fig. 1 covered all Norwegian regions, including the corre-
sponding university hospitals. Thus, all identified
Norwegian FRDA patients who were symptomatic and
diagnosed at the time of the study was probably iden-
tified. The Norwegian health care system is almost exclu-
sively public, well organized and all cases of suspected
FRDA are referred to a few specialized hospital depart-
ments and laboratories. Moreover, the study was done in
parallel with recruitment of all spinocerebellar ataxias in
southeast Norway. Some cases may however have been
missed, either as undiagnosed or presymptomatic cases at
the time of the study, or due to misdiagnosed patients lost
to follow up. Also, some late onset and atypical cases may
have been undiagnosed or missed. However, the observed
carrier frequency in southeast Norway of 1:196 was within
the range of what is expected from the prevalence in the
corresponding population in this region, supportive of a
true low prevalence as found.
In our study the most sensitive case-finding source was
through all clinical departments in Norway, through
which 97 % of all cases where identified. Due to Norway’s
small size, it was feasible to contact all clinical depart-
ments. However, as there was no perfect overlap to other
sources of patient identification, a multi-source approach
for identifying patients proved valuable, and is recom-
mended in future studies. Surprisingly, the genetic depart-
ments had only registered 87 % of all patients, but four
patients were diagnosed abroad. The largest collection of
patients found by one single source was through the
National center for rare diagnoses, Frambu, where almost
70 % of the patients were registered. Frambu is a nation-
wide competence center for rare disorders, offering infor-
mation, support and courses for FRDA families and the
results suggest that it is widely used by the patients.
According to recent studies, the GAA expansion mu-
tation may have originated in Africa up to 24 000 years
ago [7], and later gone through a genetic bottleneck in
Southern France during the last ice age. This is sup-
ported by the observation that FRDA prevalence in
Europe is decreasing along the migration route of this
population, characterized by the R1b haplotype proportion
[13]. The theory implicates a decrease in prevalence in a
north-eastern direction, consistent with the decreasingly
lower prevalence rates in Sweden and Finland, with 21 re-
ported patients in Sweden [42], and even less in Finland
[43]. The prevalence of 1:191 000 in ethnic Norwegians is
surprisingly close to the estimate of 1:208 000 from these
migration studies [9].
The higher prevalence in the north of Norway is, how-
ever, unexpected according to this theory, especially as
the R1b haplotype proportion is lower in the north [44].
None of the non-ethnic Norwegian patients lived in the
north, making the south–north gradient even more pro-
nounced among ethnic Norwegians. Nevertheless, the
same pattern is observed in Finland and has been ex-
plained by a northern migration in the 15th century [43].
In Norway, the mutation may have been brought north-
wards during one of several periods of high migration
from south to north. In addition, the population has his-
torically been less mobile in the north of Norway due to
geographical circumstances, and the level of consanguin-
ity among ethnic Norwegians seems higher here com-
pared to the south of Norway [45–48]. This could favor
preservation of recessive mutations in the population,
Wedding et al. Orphanet Journal of Rare Diseases  (2015) 10:108 Page 13 of 17
thus contributing to this regional difference. However,
the numbers are small, and coincidences may carry a
statistically large impact, leading to a type I error.
Surprisingly, 16.5 % of the alleles from almost 1400
healthy blood donors were longer than 13 repeats, i.e.
on the same level as France, where FRDA is much more
prevalent [26]. This level is seen in several Caucasian
populations, also in low-prevalent Finland. The Finnish
sample, however, contained no alleles larger than 27 re-
peats, and the missing reservoir of expansion-prone pre-
mutation alleles was suggested as a possible reason for
the very low Finnish FRDA prevalence [43]. One cannot
exclude that the higher FRDA prevalence in Norway as
compared to Finland may be partly due to the larger
proportion of premutation alleles, thus maintaining a
certain level of carriers. Carriers of premutation alleles
are in general estimated to be far less common than car-
riers of pathogenic expanded alleles, as seen also in the
blood donor population with 0.11 % permutation car-
riers vs 0.25 % mutation carriers. Thus, premutation al-
lele expansion in FRDA transmission is very unusual [1].
In our patient population we have registered 33 of 56
possible transmissions, and in these no expansions from
permutation alleles were found. However, expansions
from premutation alleles may have occurred in the car-
rier population, in which most of the pathogenic alleles
in the population occur.
Clinical characterization
Norwegian patients showed similar ataxia severity as the
recently published large European EFACTS cohort using
the FRDA validated SARA scale [41, 49] for comparison.
When compared to other case series, our patients show
closest resemblance to the German phenotypes, in par-
ticular regarding frequencies of skeletal deformities and
dysphagia. However, except for Acadian patients, who
for unknown reasons show a milder clinical picture [25],
no noticeable differences have previously been found
across ethnicities in FRDA patients. This is also ob-
served within Norway, where ethnic and non-ethnic
Norwegians were clinically similar.
Almost 40 % of the patients reported depression that
necessitated treatment, in line with the recent report by
daSilva, where 30 % of FRDA patients fulfilled the diag-
nostic criteria for major depression [50]. Depression and
psychiatric complications are increasingly being recog-
nized in FRDA, and the high number in this study
clearly demonstrates the need for a systematic assess-
ment and awareness of depression in future studies and
clinical practice.
In general, the Norwegian health care system provides
patients with good physiotherapeutic and medical
follow-up, and interestingly, the proportion of Idebenone
users was higher than in the EFACTS cohort [41].
Although Idebenone has not shown convincing thera-
peutic effect in larger studies [51, 52], the availability of
other supportive treatments could lead to the expect-
ation of a relatively good prognosis in the Norwegian pa-
tients. With lack of longitudinal data, prognosis may be
estimated by the relationship between disease duration
and severity of symptoms, or the cardiomyopathy, which
is known to be the most common cause of premature
death in FRDA patients [53]. Age at onset to wheelchair-
bound and proportion of cardiomyopathy were, however,
disappointingly similar to other case series and no sign
of prognostic differences could be found. Social support
and economic resources in addition to physical impair-
ment have been shown to have an impact in health re-
lated quality of life in FRDA patients [54]. Thus, it is
possible that quality of life evaluation could show differ-
ences compared to patients in other countries, however,
this was not included in the protocol.
As atypical cases are previously described to represent
up to ¼ of FRDA patients [3, 14, 34], the present pro-
portion of atypical patients was surprisingly low with
only two patients (7 %). These were two siblings with
hyperreflexia, disease onset at the age of 20, and a
milder course, consistent with the clinical entity of
FARR that usually shows a better prognosis than classic
FRDA [55]. The small number of atypical patients may
be coincidental due to our small sample size, but it is
also possible that atypical presentations are more often
missed and may have stayed undiagnosed.
GAA repeats
The previously described and inverse relationship be-
tween GAA1 length and age of onset [3, 56], as well as
to frataxin level [21], was confirmed. Hyper-expanded
disease-associated repeats are known to show instability
in transmission [27, 56, 57], and may explain some of
the large phenotypic interfamilial variability in neuro-
logical severity and age at onset, as seen in family 4 in
Table 2.
Frataxin
Whole blood from patients contained on average 1/10 of
the amount of frataxin found in healthy controls, with a
large variance, ranging from 1–50 % of control level. As
frataxin measurements are done in research settings
only, large differences are seen in the absolute frataxin
levels reported from different laboratories and in differ-
ent tissues. In agreement with Sacca et al., both absolute
values and relative values compared to healthy controls
are reported [58]. From our experience different product
batches gave different absolute frataxin concentrations
despite the use of recombinant frataxin as standard
curve reference, and a widespread use of the method in
clinical practice will require establishment of local
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reference values or lower inter-laboratory variance.
Frataxin is proposed to be a standardized biochemical
disease marker that may have advantages over GAA re-
peat size, by overcoming genotypic allele size related
difficulties like somatic variability/mosaicism, and com-
pound heterozygosity, as well as being suitable for
monitoring treatment. Even though a correlation is pre-
viously found between frataxin level in affected and un-
affected tissues [20], measurements of frataxin in
readily available non-affected tissues, such as blood and
cheek swabs, will only represent a surrogate marker of
the level in target tissues such as neurons, cardiomyo-
cytes and pancreatic cells. In addition, the dipstick
assay measures the frataxin 81–210 isoform, but several
isoforms of frataxin exist in different cells [59], with
different biochemical and functional properties. Thus,
it has been suggested that an expression of isoform ra-
tios between patients and healthy individuals may be an
even better surrogate outcome marker in the future
[60]. Despite all these limitations, a clear correlation
between frataxin levels in whole blood and clinical
ataxia severity, as well as age at onset and GAA1 repeat
size, could be confirmed, with age at onset being the
strongest predictor of frataxin level. No correlations were
found between frataxin and non-neurological symptoms,
which could be due to tissue-specific isoform differences
in the cardiac and pancreatic cells [59]. Interestingly, a
negative correlation between GAA1 length and frataxin
level was not only found in the patients, but also in
healthy carriers. In normal individuals, previous reports
about an association between GAA repeat length and fra-
taxin level have been conflicting [58, 61]. In this series of
27 healthy controls there is a trend towards a correlation
between GAA repeat length and frataxin level. Other still
unknown factors are probably contributing to the large
frataxin level variance in the healthy state.
Although frataxin levels are significantly different at
group level for patients and carriers, it is interesting to
note that the two clearly outlier cases with higher fra-
taxin level in the patients’ group belonged to the two
atypical FARR cases, which is consistent with previous
reports [22]. The use of frataxin measurement in the
diagnostic work-up of heterozygote individuals has pre-
viously been suggested by Sacca et al. [58, 62], and was
also found useful in this study. Based on ROC curve
analyses (Additional file 2), criteria of the measured fra-
taxin were classified and contributed to the diagnostic
work-up of four patients who all showed an ataxia
phenotype, but who were heterozygous for the GAA re-
peat expansion. One patient had a known missense mu-
tation in trans, c.467 T < C, L156P, previously described
in Sweden [15]. Consistent with its location in the C-
terminus of the mature frataxin it resulted in a typical
phenotype, and the frataxin level was well below the
patient frataxin cut-off value of 0.31 pg/μg. The sec-
ond patient heterozygous for a GAA repeat expansion
had frataxin levels in the lower range of levels seen
in the patient group (7 % of average controls), and
subsequent MLPA resulted in detection of the dele-
tion g.120032_122808del, including exon 5a. The dele-
tion is previously described in Germany [16], with a
very similar phenotype with age of onset at 9, hyper-
trophic cardiomyopathy, foot deformity, scoliosis and
axonal sensory neuropathy. Even though this patient
showed a typical FRDA phenotype, the definite gen-
etic FRDA diagnosis was first made after MLPA, pre-
ceded by a frataxin level in the lower patients’ range.
The two other heterozygous patients showed frataxin
levels within the carrier range. One had an OPA1 muta-
tion, causing mitochondrial dysfunction. This patient had
a complex phenotype, with sensory ataxia and axonal
neuropathy compatible with FRDA, but in addition a se-
vere optic atrophy, making the clinical picture more con-
sistent with a severe OPA1 phenotype [36]. Even though
optic atrophy does occur in FRDA patients it is uncom-
mon, and a primary OPA1 diagnosis is further sup-
ported by frataxin level only in the carrier range. The
other patient showed signs of childhood onset dorsal
column dysfunction consistent with FRDA, but had
additional atypical features like early onset cerebellar
atrophy, intellectual deterioration, hyperreflexia and
epilepsy as well as elevated blood lactate, clinically con-
sistent with mitochondrial dysfunction. Based on their
frataxin levels these two patients may be coincidental
carriers of the GAA triplet repeat expansion, as is ex-
pected to be seen in 1:200 Norwegians. However, based
on the knowledge of a mitochondrial role of frataxin it
could be tempting to hypothesize a possible contribu-
tion of the relative frataxin deficiency in heterozygotes,
to the severity of their mitochondrial disease.
Future perspectives
In the literature, FRDA is now clinically and genetically
well described, and in recent years the understanding of
the molecular pathogenesis has improved. This has
paved the way for possible treatments, and several clin-
ical trials on different compounds are on-going. Fra-
taxin levels are increasingly being used as an outcome
measure in clinical trials, and it is important to estab-
lish reference values and baseline data in well charac-
terized patients, as we aimed to do for the Norwegian
population. A thorough characterization of the nation’s
patients is crucial for participation in clinical trials, as
well as for implementing treatments when eventually
available. This study could pave the way for inclusion
of the highly motivated Norwegian patients in future
clinical trials.
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Conclusions
This study is not only the first comprehensive study of
genetically confirmed Friedreich ataxia in Scandinavia,
but also one of the first studies that describes in detail
both clinical and molecular features of a complete na-
tional collection of FRDA patients. The strength of this
study is the inclusion of all diagnosed patients within a
country, which reduces selection bias and thereby gives
a good overview of the spectrum of the disease. FRDA is
present in Norway with a prevalence of 1:176 000 (1:191
000 among ethnic Norwegians), as expected from clin-
ical reports and genetic population studies. An unex-
pected significant south–north gradient is seen. The
assessment of frataxin proved useful for diagnostics,
especially in heterozygous symptomatic cases.
Additional files
Additional file 1: Meiotic instability of GAA repeats analyzed by
differences in GAA repeat expansion sizes in parents and children.
(DOCX 22 kb)
Additional file 2: ROC curves based on measuring frataxin from
whole blood in FRDA patients, carriers and healthy controls.
(DOCX 38 kb)
Abbreviations
FRDA: Friedreich ataxia; GAA1: shortest GAA repeat expansion; GAA2: longest
GAA repeat expansion; MLPA: Multiplex ligand-dependent probe amplification;
SARA: Scale for the Assessment and Rating of Ataxia SARA.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: IMW, MK, SPH, KKS, TF, PMK, TB,
CMET. Investigated the patients: IMW. Performed the experiments: IMW, MK,
SPH, TB. Analyzed the data: IMW, MK, SPH, KKS, TF, PMK, TB, CMET.
Contributed reagents/materials/analysis tools: PMK, CMET. Drafted the
manuscript: IMW, CMET. All authors critically read, revised and approved the
final manuscript.
Acknowledgements
We are very grateful to the patients and their families for their very kind
cooperation. We also thank Thore Egeland for assistance in the power
analysis and Hilde Eldevik Rusaas for performing the Southern Blot analyses.
We are very grateful to clinicians and colleagues who helped us collect the
patients, particularly Christoph Wahl, Jasmina Tajsic, Ragnhild Glad, Bente
Ødegaard, Geir Bråthen, Jan Aasly, Elisabet Aune, Charalampos Tzoulis,
Laurence Bindoff, Jeanette Koht, Magnhild Rasmussen and Jon Barlinn. A
special thanks to Kaja Giltvedt and FRAMBU Centre for Rare Disorders.
Author details
1Department of Neurology, Oslo University Hospital, Ullevaal 0407, Oslo,
Norway. 2Department of Medical Genetics, Oslo University Hospital, Ullevaal
0407Oslo, Norway. 3University of Oslo, Faculty of Medicine, Oslo, Norway.
4Department of Clinical Science, University of Bergen, Bergen, Norway.
5Center for Medical Genetics and Molecular Medicine, Haukeland University
Hospital, Bergen, Norway.
Received: 6 July 2015 Accepted: 25 August 2015
References
1. Bidichandani SI, Delatycki MB. Friedreich Ataxia. Pagon R, Adam M,
HH A, editors. Seattle, USA: University of Washington, Seattle; 1998
(Updated 2014 Jul 24).
2. Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256
Suppl 1:3–8. doi:10.1007/s00415-009-1002-3.
3. Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, et al. Clinical
and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med.
1996;335(16):1169–75. doi:10.1056/nejm199610173351601.
4. Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features
of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem.
2013;126 Suppl 1:103–17. doi:10.1111/jnc.12317.
5. Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology
revised. J Neuropathol Exp Neurol. 2013;72(2):78–90. doi:10.1097/
NEN.0b013e31827e5762.
6. Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families
with an analysis of early diagnostic criteria and intrafamilial clustering of
clinical features. Brain. 1981;104(3):589–620.
7. Labuda M, Labuda D, Miranda C, Poirier J, Soong BW, Barucha NE, et al.
Unique origin and specific ethnic distribution of the Friedreich ataxia GAA
expansion. Neurology. 2000;54(12):2322–4.
8. Skre H. Friedreich’s ataxia in Western Norway. Clin Genet. 1975;7(4):287–98.
9. Koht J, Tallaksen CM. Cerebellar ataxia in the eastern and southern
parts of Norway. Acta Neurol Scand Suppl. 2007;187:76–9. doi:10.1111/
j.1600-0404.2007.00853.x.
10. Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence
of hereditary ataxia and spastic paraplegia in southeast Norway: a population-
based study. Brain. 2009;132(Pt 6):1577–88. doi:10.1093/brain/awp056.
11. Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F,
et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic
GAA triplet repeat expansion. Science. 1996;271(5254):1423–7.
12. Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, et al.
The spectrum of clinical disease caused by the A467T and W748S POLG
mutations: a study of 26 cases. Brain. 2006;129(Pt 7):1685–92. doi:10.1093/
brain/awl097.
13. Vankan P. Prevalence gradients of Friedreich’s ataxia and R1b haplotype in
Europe co-localize, suggesting a common Palaeolithic origin in the Franco-
Cantabrian ice age refuge. J Neurochem. 2013;126 Suppl 1:11–20.
doi:10.1111/jnc.12215.
14. Lamont PJ, Davis MB, Wood NW. Identification and sizing of the GAA
trinucleotide repeat expansion of Friedreich’s ataxia in 56 patients. Clinical
and genetic correlates. Brain. 1997;120(Pt 4):673–80.
15. Cossee M, Durr A, Schmitt M, Dahl N, Trouillas P, Allinson P, et al.
Friedreich’s ataxia: point mutations and clinical presentation of compound
heterozygotes. Ann Neurol. 1999;45(2):200–6.
16. Zuhlke CH, Dalski A, Habeck M, Straube K, Hedrich K, Hoeltzenbein M, et al.
Extension of the mutation spectrum in Friedreich’s ataxia: detection of an
exon deletion and novel missense mutations. Eur J Hum Genet.
2004;12(11):979–82. doi:10.1038/sj.ejhg.5201257.
17. Anheim M, Mariani LL, Calvas P, Cheuret E, Zagnoli F, Odent S, et al.
Exonic deletions of FXN and early-onset Friedreich ataxia. Arch Neurol.
2012;69(7):912–6. doi:10.1001/archneurol.2011.834.
18. Pastore A, Puccio H. Frataxin: a protein in search for a function.
J Neurochem. 2013;126 Suppl 1:43–52. doi:10.1111/jnc.12220.
19. Matilla-Duenas A, Ashizawa T, Brice A, Magri S, McFarland KN,
Pandolfo M, et al. Consensus paper: pathological mechanisms
underlying neurodegeneration in spinocerebellar ataxias. Cerebellum
(London, England). 2014;13(2):269–302. doi:10.1007/s12311-013-0539-y.
20. Nachbauer W, Wanschitz J, Steinkellner H, Eigentler A, Sturm B, Hufler K, et
al. Correlation of frataxin content in blood and skeletal muscle endorses
frataxin as a biomarker in Friedreich ataxia. Mov Disord. 2011;26(10):1935–8.
doi:10.1002/mds.23789.
21. Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF,
et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of
Friedreich ataxia. Mol Genet Metab. 2010;101(2–3):238–45. doi:10.1016/
j.ymgme.2010.07.001.
22. Deutsch EC, Oglesbee D, Greeley NR, Lynch DR. Usefulness of frataxin
immunoassays for the diagnosis of Friedreich ataxia. J Neurol Neurosurg
Psychiatry. 2014;85(9):994–1002. doi:10.1136/jnnp-2013-306788.
23. Pandolfo M. Molecular basis of Friedreich ataxia. Mov Disord.
2001;16(5):815–21.
Wedding et al. Orphanet Journal of Rare Diseases  (2015) 10:108 Page 16 of 17
24. Pandolfo M. Friedreich ataxia. Handb Clin Neurol. 2012;103:275–94.
doi:10.1016/b978-0-444-51892-7.00017-6.
25. Montermini L, Richter A, Morgan K, Justice CM, Julien D, Castellotti B, et al.
Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet
repeat expansion. Ann Neurol. 1997;41(5):675–82. doi:10.1002/ana.410410518.
26. Cossee M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, Mandel JL,
et al. Evolution of the Friedreich’s ataxia trinucleotide repeat expansion:
founder effect and premutations. Proc Natl Acad Sci U S A. 1997;94(14):7452–7.
27. Montermini L, Andermann E, Labuda M, Richter A, Pandolfo M, Cavalcanti F,
et al. The Friedreich ataxia GAA triplet repeat: premutation and normal
alleles. Hum Mol Genet. 1997;6(8):1261–6.
28. Statistics Norway. www.ssb.no. Accessed 30 November 2014.
29. Tallaksen CME, Dürr A. SPATAX- European Network for Hereditary
Spinocerebellar Degenerative Disorders. Acta Neurol Scand.
2003;107(6):432–3. doi:10.1034/j.1600-0404.2003.00125_18.x.
30. SPATAX Network. https://spatax.wordpress.com. Accessed 01 January 2013.
31. Schmitz-Hubsch T, du Montcel S, Baliko L, Berciano J, Boesch S, Depondt C.
Scale for the assessment and rating of ataxia: development of a new clinical
scale. Neurology. 2006;66:1717–20.
32. Ciotti P, Di Maria E, Bellone E, Ajmar F, Mandich P. Triplet repeat
primed PCR (TP PCR) in molecular diagnostic testing for Friedreich
ataxia. J Mol Diagn. 2004;6(4):285–9. doi:10.1016/s1525-1578(10)60523-5.
33. Pandolfo M. Friedreich ataxia: Detection of GAA repeat expansions and
frataxin point mutations. Methods Mol Med. 2006;126:197–216. doi:10.1385/
1-59745-088-x:197.
34. Schols L, Amoiridis G, Przuntek H, Frank G, Epplen JT, Epplen C. Friedreich’s
ataxia. Revision of the phenotype according to molecular genetics. Brain.
1997;120(Pt 12):2131–40.
35. Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF. Lateral-flow immunoassay
for the frataxin protein in Friedreich’s ataxia patients and carriers. Mol Genet
Metab. 2008;94(4):491–7. doi:10.1016/j.ymgme.2008.03.019.
36. Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-
Grumbach M, et al. Multi-system neurological disease is common in patients
with OPA1 mutations. Brain. 2010;133(Pt 3):771–86. doi:10.1093/brain/awq007.
37. Filla A, DeMichele G, Caruso G, Marconi R, Campanella G. Genetic data and
natural history of Friedreich’s disease: a study of 80 Italian patients. J Neurol.
1990;237(6):345–51.
38. Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E, et al.
Clinical and genetic study of Friedreich ataxia in an Australian population.
Am J Med Genet. 1999;87(2):168–74.
39. McCabe DJ, Ryan F, Moore DP, McQuaid S, King MD, Kelly A, et al. Typical
Friedreich’s ataxia without GAA expansions and GAA expansion without
typical Friedreich’s ataxia. J Neurol. 2000;247(5):346–55.
40. Salehi MH, Houshmand M, Aryani O, Kamalidehghan B, Khalili E. Molecular
and clinical investigation of Iranian patients with Friedreich ataxia. Iran
Biomed J. 2014;18(1):28–33.
41. Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, et al.
Biological and clinical characteristics of the European Friedreich’s Ataxia
Consortium for Translational Studies (EFACTS) cohort: a cross-sectional
analysis of baseline data. Lancet Neurol. 2015;14(2):174–82. doi:10.1016/
s1474-4422(14)70321-7.
42. Jonasson J, Juvonen V, Sistonen P, Ignatius J, Johansson D, Bjorck EJ, et al.
Evidence for a common Spinocerebellar ataxia type 7 (SCA7) founder
mutation in Scandinavia. Eur J Hum Genet. 2000;8(12):918–22. doi:10.1038/
sj.ejhg.5200557.
43. Juvonen V, Kulmala SM, Ignatius J, Penttinen M, Savontaus ML. Dissecting
the epidemiology of a trinucleotide repeat disease - example of FRDA in
Finland. Hum Genet. 2002;110(1):36–40. doi:10.1007/s00439-001-0642-x.
44. Dupuy BM, Stenersen M, Lu TT, Olaisen B. Geographical heterogeneity of
Y-chromosomal lineages in Norway. Forensic Sci Int. 2006;164(1):10–9.
doi:10.1016/j.forsciint.2005.11.009.
45. Gedde-Dahl Jr T. Population structure in Norway. Inbreeding, distance and
kinship. Hereditas. 1973;73(2):211–32.
46. Saugstad LF. Inbreeding in Norway. Ann Hum Genet. 1977;40(4):481–91.
47. Surén P, Grjibovski A, Stoltenberg C. Inngifte i Norge. Omfang og
medisinske konsekvenser. Oslo: Norwegian Institute of Public Health; 2007.
48. Saugstad LF. The relationship between inbreeding, migration and
population density in Norway. Ann Hum Genet. 1977;40(3):331–41.
49. Burk K, Malzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hubsch T, et al.
Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov
Disord. 2009;24(12):1779–84. doi:10.1002/mds.22660.
50. Silva CB, Yasuda CL, D'Abreu A, Cendes F, Lopes-Cendes I, Franca Jr MC.
Neuroanatomical correlates of depression in Friedreich’s ataxia: a voxel-
based morphometry study. Cerebellum. 2013;12(3):429–36. doi:10.1007/
s12311-012-0424-0.
51. Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL,
et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month
phase III study (IONIA). Am Heart J. 2011;161(3):639–45.e1. doi:10.1016/
j.ahj.2010.10.038.
52. Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of
neurological efficacy of idebenone in pediatric patients with Friedreich’s
ataxia: data from a 6-month controlled study followed by a 12-month
open-label extension study. J Neurol. 2012;259(2):284–91. doi:10.1007/
s00415-011-6174-y.
53. Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR,
et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1–2):46–9.
doi:10.1016/j.jns.2011.05.023.
54. Wilson CL, Fahey MC, Corben LA, Collins VR, Churchyard AJ, Lamont PJ, et al.
Quality of life in Friedreich ataxia: what clinical, social and demographic
factors are important? Eur J Neurol. 2007;14(9):1040–7. doi:10.1111/
j.1468-1331.2007.01881.x.
55. Coppola G, De Michele G, Cavalcanti F, Pianese L, Perretti A, Santoro L, et al.
Why do some Friedreich’s ataxia patients retain tendon reflexes? A clinical,
neurophysiological and molecular study. J Neurol. 1999;246(5):353–7.
56. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G,
et al. The relationship between trinucleotide (GAA) repeat length and
clinical features in Friedreich ataxia. Am J Hum Genet. 1996;59(3):554–60.
57. Ohshima K, Sakamoto N, Labuda M, Poirier J, Moseley ML, Montermini L,
et al. A nonpathogenic GAAGGA repeat in the Friedreich gene: implications
for pathogenesis. Neurology. 1999;53(8):1854–7.
58. Sacca F, Puorro G, Antenora A, Marsili A, Denaro A, Piro R, et al. A combined
nucleic acid and protein analysis in Friedreich ataxia: implications for
diagnosis, pathogenesis and clinical trial design. PLoS One. 2011;6(3),
e17627. doi:10.1371/journal.pone.0017627.
59. Xia H, Cao Y, Dai X, Marelja Z, Zhou D, Mo R, et al. Novel frataxin isoforms
may contribute to the pathological mechanism of Friedreich ataxia. PLoS
One. 2012;7(10), e47847. doi:10.1371/journal.pone.0047847.
60. De Michele G, Filla A. Movement disorders: Friedreich ataxia today-preparing
for the final battle. Nat Rev Neurol. 2015;11(4):188–90. doi:10.1038/
nrneurol.2015.33.
61. Boehm T, Scheiber-Mojdehkar B, Kluge B, Goldenberg H, Laccone F, Sturm
B. Variations of frataxin protein levels in normal individuals. Neurol Sci.
2011;32(2):327–30. doi:10.1007/s10072-010-0326-1.
62. Sacca F, Marsili A, Puorro G, Antenora A, Pane C, Tessa A, et al. Clinical use
of frataxin measurement in a patient with a novel deletion in the FXN gene.
J Neurol. 2013;260(4):1116–21. doi:10.1007/s00415-012-6770-5.
63. Werdelin L, Keiding N. Hereditary ataxias: epidemiological aspects.
Neuroepidemiology. 1990;9(6):321–31.
64. Gudmundsson KR. Prevalence and occurrence of some rare neurological
diseases in Iceland. Acta Neurol Scand. 1969;45(1):114–8.
65. Marino TC, Zaldivar YG, Mesa JM, Mederos LA, Rodriguez RA, Gotay DA,
et al. Low predisposition to instability of the Friedreich ataxia gene in Cuban
population. Clin Genet. 2010;77(6):598–600. doi:10.1111/j.1399-0004.2009.01361.x.
66. Singh I, Faruq M, Mukherjee O, Jain S, Pal PK, Srivastav MV, et al. North and
South Indian populations share a common ancestral origin of Friedreich’s
ataxia but vary in age of GAA repeat expansion. Ann Hum Genet.
2010;74(3):202–10. doi:10.1111/j.1469-1809.2010.00569.x.
67. Monticelli A, Giacchetti M, De Biase I, Pianese L, Turano M, Pandolfo M, et al.
New clues on the origin of the Friedreich ataxia expanded alleles from the
analysis of new polymorphisms closely linked to the mutation. Hum Genet.
2004;114(5):458–63. doi:10.1007/s00439-004-1089-7.
Wedding et al. Orphanet Journal of Rare Diseases  (2015) 10:108 Page 17 of 17
